Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Democratizing Specialized Care in the Digital Age: Project ECHO as a Learning Environment for Continuing Professional Development.

Healthcare (Basel, Switzerland)·2026
Same author

Neutrophil extracellular traps and peptidylarginine deiminase 4-mediated inflammasome activation link diabetes to cardiorenal injury and heart failure.

European heart journal·2025
Same author

A GPVI-platelet-neutrophil-NET axis drives systemic sclerosis.

bioRxiv : the preprint server for biology·2025
Same author

Sex-specific NLRP3 activation in neutrophils promotes neutrophil recruitment and NETosis in the murine model of diffuse alveolar hemorrhage.

Frontiers in immunology·2024
Same author

Reflections on Targeting Neutrophil Extracellular Traps in Deep Vein Thrombosis.

Arteriosclerosis, thrombosis, and vascular biology·2024
Same author

Neutrophil NLRP3 promotes cardiac injury following acute myocardial infarction through IL-1β production, VWF release and NET deposition in the myocardium.

Scientific reports·2024
Same journal

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

Oncoimmunology·2026
Same journal

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Oncoimmunology·2026
Same journal

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.

Oncoimmunology·2026
Same journal

The peripheral immune landscape of human breast cancer.

Oncoimmunology·2026
Same journal

Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity.

Oncoimmunology·2026
Same journal

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology·2026
See all related articles

Related Experiment Video

Updated: May 21, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Targeting platelet function to improve drug delivery.

Mélanie Demers1, Denisa D Wagner

  • 1Immune Disease Institute; Program in Cellular and Molecular Medicine; Children's Hospital Boston; Department of Pediatrics; Harvard Medical School; Boston, MA USA.

Oncoimmunology
|June 22, 2012
PubMed
Summary
This summary is machine-generated.

Low platelet counts can cause tumor bleeding, enhancing drug delivery and cancer treatment efficacy. Combining anti-platelet therapies with cancer drugs offers a promising strategy for improved outcomes with fewer side effects.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Related Experiment Videos

Last Updated: May 21, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Tumor hemorrhage is a known complication.
  • Drug delivery to solid tumors remains a challenge in cancer therapy.
  • Platelets play a role in hemostasis and tumor biology.

Purpose of the Study:

  • To investigate the potential of thrombocytopenia-induced tumor hemorrhage as a method to improve drug delivery.
  • To evaluate the combined efficacy of anti-platelet treatment and therapeutic drugs in cancer treatment.

Main Methods:

  • Inducing thrombocytopenia (low platelet count) in tumor models.
  • Assessing the impact of induced hemorrhage on drug penetration and distribution within tumors.
  • Administering anti-platelet agents in combination with standard chemotherapeutic drugs.
  • Evaluating tumor response and overall survival in treated subjects.

Main Results:

  • Thrombocytopenia-induced tumor hemorrhage significantly enhanced the delivery of therapeutic agents to tumor tissues.
  • The combination therapy demonstrated improved anti-tumor activity compared to monotherapy.
  • Minimal systemic side effects were observed, suggesting a favorable safety profile.

Conclusions:

  • Thrombocytopenia-induced tumor hemorrhage is a viable strategy to improve drug delivery and efficacy in cancer treatment.
  • Combining anti-platelet therapy with conventional cancer drugs represents a promising approach for enhancing treatment outcomes.
  • This approach offers a novel method to increase drug efficacy while minimizing adverse effects in cancer patients.